Government Policy & Regulation - US President Trump is urging 17 pharmaceutical manufacturers to voluntarily lower US prescription drug prices within 60 days to match global prices [1] - The call includes extending most favored nation (MFN) pricing to Medicaid [2] - Guaranteeing MFN pricing for newly launched drugs is also requested [2] - The request includes returning increased revenues from abroad to American patients and taxpayers [2] - Direct purchasing at MFN pricing is another point in the request [2] Industry Impact & Challenges - Implementing MFN pricing for newly launched drugs presents challenges, as US is often the initial launch market [3] - The industry will be watching the responses of companies like Lily, Pfizer, and AbbVie [4]